Precision Measurement of Trident Production in Strong Electromagnetic Fields

We demonstrate experimentally that the trident process $e^-\rightarrow e^-e^+e^-$ in a strong external field, with a spatial extension comparable to the effective radiation length, is well understood theoretically. The experiment, conducted at CERN, probes values for the strong field parameter $\chi$ up to 2.4. Experimental data and theoretical expectations using the Local Constant Field Approximation show remarkable agreement over almost 3 orders of magnitude in yield.Comment: 4 pages, 2 figure

Differential Measurement of Trident Production in Strong Electromagnetic Fields

In this paper, we present experimental results and numerical simulations of trident production, $e^-\rightarrow e^-e^+e^-$, in a strong electromagnetic field. The experiment was conducted at CERN for the purpose of probing the strong-field parameter $\chi$ up to 2.4, using a 200 GeV electron beam penetrating a 400 $\mu$m thick germanium crystal oriented along the $\langle 110\rangle$ axis. For the current experimental parameters we found that the trident process is primarily a two-step process, and show remarkable agreement between theoretical predictions and experimental data. This paper is an extension of the previously published paper (Phys. Rev. Lett. 130, 071601 (2023)) and features new analysis differential in the energy of the produced positron and electron in the trident process. Even for the more demanding differential analysis, we find good agreement between theoretical predictions and experimental data, while a slight discrepancy is found in the high energy tail of the trident spectrum. This discrepancy could be an indication of the direct process, but further investigation is needed due to the large uncertainties in this part of the spectrum. Finally we present a suggestion for a future experiment, aiming to probe the direct process using thin crystals

INTEGRAL Broadband X-ray spectrum of the intermediate polar V709 Cas

We present the hard X-ray time-averaged spectrum of the intermediate polar V709 Cas observed with INTEGRAL. We performed the observation using data from the IBIS/ISGRI instrument in the 20-100 keV energy band and from JEM-X at lower energy (5-20 keV). Using different multi-temperature and density X-ray post-shock models we measured a improved post-shock temperature of ~40 keV and estimated the V709 Cas mass to be 0.82(+0.12/-0.25} Msun. We compare the resulting spectral parameters with previously reported BeppoSAX and RXTE observations.Comment: 5 pages, 3 figures, 2 tables, accepted for publication in A&

Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels

Introduction. Management of phenylketonuria (PKU) is achieved through low-phenylalanine (Phe) diet, supplemented with low-protein food and mixture of free-synthetic (FS) amino acid (AA). Casein glycomacropeptide (CGMP) is a natural peptide released in whey during cheese-making and does not contain Phe. Lacprodan® CGMP-20 used in this study contained a small amount of Phe due to minor presence of other proteins/peptides. Objective. The purpose of this study was to compare absorption of CGMP-20 to FSAA with the aim of evaluating short-term effects on plasma AAs as well as biomarkers related to food intake. Methods. This study included 8 patients, who had four visits and tested four drink mixtures (DM1–4), consisting of CGMP, FSAA, or a combination. Plasma blood samples were collected at baseline, 15, 30, 60, 120, and 240 minutes (min) after the meal. AA profiles and ghrelin were determined 6 times, while surrogate biomarkers were determined at baseline and 240 min. A visual analogue scale (VAS) was used for evaluation of taste and satiety. Results. The surrogate biomarker concentrations and VAS scores for satiety and taste were nonsignificant between the four DMs, and there were only few significant results for AA profiles (not Phe). Conclusion. CGMP and FSAA had the overall same nonsignificant short-term effect on biomarkers, including Phe. This combination of FSAA and CGMP is a suitable supplement for PKU patients

A splice-site variant in the lncRNA gene RP1-140A9.1 cosegregates in the large Volkmann cataract family

Purpose: To identify the mutation for Volkmann cataract (CTRCT8) at 1p36.33. Methods: The genes in the candidate region 1p36.33 were Sanger and parallel deep sequenced, and informative single nucleotide polymorphisms (SNPs) were identified for linkage analysis. Expression analysis with reverse transcription polymerase chain reaction (RT-PCR) of the candidate gene was performed using RNA from different human tissues. Quantitative transcription polymerase chain reaction (qRT-PCR) analysis of the GNB1 gene was performed in affected and healthy individuals. Bioinformatic analysis of the linkage regions including the candidate gene was performed. Results: Linkage analysis of the 1p36.33 CCV locus applying new marker systems obtained with Sanger and deep sequencing reduced the candidate locus from 2.1 Mb to 0.389 Mb flanked by the markers STS-22AC and rs549772338 and resulted in an logarithm of the odds (LOD) score of Z = 21.67. The identified mutation, rs763295804, affects the donor splice site in the long non-coding RNA gene RP1–140A9.1 (ENSG00000231050). The gene including splice-site junctions is conserved in primates but not in other mammalian genomes, and two alternative transcripts were shown with RT–PCR. One of these transcripts represented a lens cell–specific transcript. Meta-analysis of the Cross-Linking-Immuno-Precipitation sequencing (CLIP-Seq) data suggested the RNA binding protein (RBP) eIF4AIII is an active counterpart for RP1–140A9.1, and several miRNA and transcription factors binding sites were predicted in the proximity of the mutation. ENCODE DNase I hypersensitivity and histone methylation and acetylation data suggest the genomic region may have regulatory functions. Conclusions: The mutation in RP1–140A9.1 suggests the long non-coding RNA as the candidate cataract gene associated with the autosomal dominant inherited congenital cataract from CCV. The mutation has the potential to destroy exon/intron splicing of both transcripts of RP1–140A9.1. Sanger and massive deep resequencing of the linkage region failed to identify alternative candidates suggesting the mutation in RP1–140A9.1 is causative for the CCV phenotype

Observing GRBs with the LOFT Wide Field Monitor

LOFT (Large Observatory For X-ray Timing) is one of the four candidate missions currently under assessment study for the M3 mission in ESAs Cosmic Vision program to be launched in 2024. LOFT will carry two instruments with prime sensitivity in the 2-30 keV range: a 10 m2 class large area detector (LAD) with a <1° collimated field of view and a wide field monitor (WFM) instrument. The WFM is based on the coded mask principle, and 5 camera units will provide coverage of more than 1/3 of the sky. The prime goal of the WFM is to detect transient sources to be observed by the LAD. With its wide field of view and good energy resolution of <500 eV, the WFM will be an excellent instrument for detecting and studying GRBs and X-ray flashes. The WFM will be able to detect ~150 gamma ray bursts per year, and a burst alert system will enable the distribution of ~100 GRB positions per year with a ~1 arcmin location accuracy within 30 s of the burst

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study

Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control.One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p<0.001; body weight, -1.74 kg (-3.32; -0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated.In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted.ClinicalTrials.gov NCT00118937